



## AMENDMENTS TO THE CLAIMS

The following is a complete, marked up listing of revised claims with a status identifier in parentheses, underlined text indicating insertions, and strikethrough and/or double-bracketed text indicating deletions.

## LISTING OF CLAIMS


1-12. (CANCELED)

13. (CURRENTLY AMENDED) An organophosphorus compound  
~~Organophosphorus compounds according to one of the general formulas I', II' or III'~~



wherein A is selected from the group which consists of a (C<sub>1-9</sub>) alkylene residue; which may comprise one or more double bonds and may be substituted with hydroxy,

halogen, amino, oxo groups with branched or unbranched C<sub>1-9</sub> alkyl groups and C<sub>2-9</sub> alkenyl groups, wherein the C<sub>1-9</sub> alkyl groups and C<sub>2-9</sub> alkenyl groups may be substituted with hydrogen, hydroxy, amino, halogen and oxo groups, -C-O-C- and -C-N-C-, wherein the carbon atoms of -C-O-C- and -C-N-C- may be substituted with an alkyl having up to 7 carbon atoms or hydroxy groups, or in which A is of the following formula (II):




wherein one or more of the carbon atoms selected from the group C<sub>3</sub>, C<sub>4</sub>, C<sub>5</sub>, together with their substituents, may also be absent, and at least one substituent present in the range from B<sub>1</sub> to B<sub>10</sub> is a C<sub>1-8</sub>-cycloalkyl-(C<sub>0-9</sub>)-alkyl group, wherein both the C<sub>1-8</sub> cycloalkyl group and the C<sub>0-9</sub> alkyl group may comprise one or more double bonds and one or two carbon atoms of the cycloalkyl group may be replaced by nitrogen, oxygen or sulfur atoms, and wherein both the cycloalkyl group and the alkyl group may be substituted with hydroxy, halogen, amino, oxo groups with branched or unbranched C<sub>1-9</sub> alkyl groups and C<sub>2-9</sub> alkenyl groups, wherein the C<sub>1-9</sub> alkyl groups and C<sub>2-9</sub> alkenyl groups may be substituted with hydrogen, hydroxy, amino, halogen and oxo groups, and the remaining substituents B<sub>1</sub> to B<sub>10</sub> present are selected from the group which consists of hydrogen, hydroxy, halogen, amino groups, C<sub>1-26</sub> alkyl residues; C<sub>1-26</sub> alkoxy residues, C<sub>1-26</sub>-alkoxy-C<sub>1-26</sub>-alkyl residues or both substituents of a C atom together form an oxo group, wherein each C<sub>1-26</sub> alkyl residue and each C<sub>1-26</sub> alkoxy residue may be branched or unbranched and be saturated or unsaturated with one or more double bonds and may be substituted with hydroxy, amino, halogen and oxo groups, in which R<sub>1</sub> is selected from the group which consists of 5- and 6-membered heterocycles with at least one ring nitrogen atom or a polycyclic carbon with at least one of these heterocycles, wherein at least one of these nitrogen atoms belongs to a hydroxamic acid group or a hydroxamic acid ester group, and may be saturated or unsaturated with one or more double or triple bonds and may thus also be aromatic and may be substituted with hydroxy, halogen,

amino, oxo groups and with branched or unbranched C<sub>1-9</sub> alkyl groups and C<sub>2-9</sub> alkenyl groups, wherein the C<sub>1-9</sub> alkyl groups and C<sub>2-9</sub> alkenyl groups may be saturated or unsaturated with one or more double or triple bonds and may be substituted with hydrogen, hydroxy, amino, halogen and oxo groups, wherein the nitrogen atom of the hydroxamic acid group or hydroxamic acid ester group is substituted with OR<sub>51</sub> and

R<sub>5</sub> is selected from the group which consists of hydrogen, substituted and unsubstituted C<sub>1-9</sub> alkyl, substituted and unsubstituted hydroxy-C<sub>1-9</sub>-alkyl, substituted and unsubstituted C<sub>1-9</sub> alkenyl, substituted and unsubstituted C<sub>1-9</sub> alkenyl, substituted and unsubstituted aryl, substituted and unsubstituted acyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted aralkyl, substituted and unsubstituted heterocyclic residue, in which R<sub>3</sub> and R<sub>4</sub> are identical or different and are selected from the group which consists of hydrogen, substituted and unsubstituted C<sub>1-26</sub> alkyl, hydroxy-C<sub>1-26</sub> alkyl; substituted and unsubstituted aryl, substituted and unsubstituted acyl, substituted and unsubstituted aralkyl, substituted and unsubstituted C<sub>1-26</sub> alkenyl, substituted and unsubstituted C<sub>1-26</sub> alkenyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclic residue, halogen, OX<sub>3</sub> and OX<sub>4</sub>,


wherein X<sub>3</sub> and X<sub>4</sub> are identical or different and are selected from the group which consists of hydrogen, substituted and unsubstituted C<sub>1-26</sub> alkyl, substituted and unsubstituted hydroxy-C<sub>1-26</sub> alkyl, substituted and unsubstituted aryl, substituted and unsubstituted aralkyl, substituted and unsubstituted C<sub>1-26</sub> alkenyl, substituted and unsubstituted C<sub>1-26</sub> alkenyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclic residue, a silyl, a cation of an organic and inorganic base; in particular a metal of main groups I, II or III of the periodic system; ammonium, substituted ammonium and ammonium compounds derived from ethylenediamine or amino acids, and the pharmaceutically acceptable salts, esters and amides thereof and salts of the esters.

14. (CURRENTLY AMENDED) The compound Compound according to claim 13, wherein characterised in that the organophosphorus compounds are of the formula (III)




wherein R<sub>3</sub> is R<sub>5</sub> is selected from a group consisting of preferably hydrogen, methyl, ethyl, and an amide residue and X<sub>4</sub> is selected from the group which consists of hydrogen, sodium, potassium, methyl, ethyl.

15. (CURRENTLY AMENDED) The compound Compound according to claim 13, associated with cations X<sub>3</sub> and X<sub>4</sub> according to one of formulas I'', II'' or III''



wherein X<sub>3</sub> and X<sub>4</sub> are independently selected from a group consisting of hydrogen, a (C<sub>1-3</sub>) alkyl, a metal from groups I, II or III of the periodic table, ammonium, substituted ammonium, and ammonium compounds derived from ethylenediamine or amino acids characterised in that the organophosphorus compounds are of the formula (IV)



wherein  $X_3$  and  $X_4$  are identical or different and are selected from the group which consists of hydrogen, a  $(C_{1-3})$  alkyl, a metal of main groups I, II or III of the periodic system, ammonium, substituted ammonium, or ammonium compounds derived from ethylenediamine or amino acids.

16. (CURRENTLY AMENDED) The compound according to claim 13, wherein characterised in that  $X_3$  and  $X_4$  are independently identical or different and are selected from a the group consisting which consists of hydrogen, sodium, potassium, methyl and, ethyl.

17. (CURRENTLY AMENDED) The compound according to claim 13, wherein characterised in that A is selected from the group consisting which consists of alkylene, alkenylene, hydroxyalkylene and oxoalkylene.

18. (CURRENTLY AMENDED) The compound according to claim 17, wherein characterised in that A is selected such that three atoms are present between the nitrogen atom of the heterocyclic group and the phosphorus atom, and further wherein A is selected from a group consisting of preferably a-methylene, hydroxymethylene, ethylene, ethenylene and/or hydroxyethylene.

19-22. (CANCELED)

23. (CURRENTLY AMENDED) A pharmaceutical Pharmaceutical preparation for the therapeutic and prophylactic treatment of infectious processes comprising:  
, characterised in that the preparation contains an active content of a first pharmaceutically active at least one organophosphorus compound according to claim 13; and  
together with a pharmaceutically acceptable excipient.

24. (CURRENTLY AMENDED) A pharmaceutical Pharmaceutical preparation according to claim 23, further comprising:

a second pharmaceutically active characterised in that the preparation contains another pharmaceutical active substance.

\* \* \* \* \*

END OF LISTING OF CLAIMS

THE REMAINDER OF THE PAGE HAS BEEN LEFT BLANK INTENTIONALLY